Anti-Diabetes Drugs - Eastern Africa

The Anti-Diabetes Drugs market in Eastern Africa is anticipated to witness a significant increase in revenue, with projections indicating that it will reach a staggering US$276.70m by the year 2024.
Moreover, it is expected to exhibit a promising annual growth rate (CAGR 2024-2029) of 7.95%, ultimately leading to a market volume of US$405.60m by 2029.
It is worth noting that in terms of global comparison, United States is set to generate the highest revenue, amounting to a remarkable US$37.84bn in 2024.
The demand for anti-diabetes drugs in Eastern Africa is increasing due to the rising prevalence of diabetes in the region.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The prevalence of diabetes in Eastern Africa has been increasing in recent years, leading to a growing demand for anti-diabetes drugs in the region.

Customer preferences: Patients in Eastern Africa prefer oral medications for the treatment of diabetes, as injections are often seen as painful and inconvenient. Additionally, there is a preference for generic drugs due to their lower cost compared to branded medications.

Trends in the market: There has been a shift towards the use of newer, more expensive medications in the treatment of diabetes in Eastern Africa. This is due to an increase in awareness and education about the benefits of these drugs, as well as the availability of more affordable versions of these medications. There is also a growing trend towards the use of combination therapies, as they offer a more effective treatment option for patients with diabetes.

Local special circumstances: The lack of access to healthcare facilities and trained medical personnel in some areas of Eastern Africa has led to a reliance on traditional medicine for the treatment of diabetes. This has resulted in a significant proportion of patients not receiving proper treatment for their condition, leading to a higher prevalence of complications and mortality rates.

Underlying macroeconomic factors: The rising prevalence of diabetes in Eastern Africa can be attributed to a number of factors, including urbanization, changes in lifestyle and diet, and an aging population. The region's economic growth has led to an increase in disposable income, which has in turn led to changes in dietary habits and a decrease in physical activity. Additionally, the lack of access to affordable and healthy food options has contributed to the rise in diabetes cases in the region.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.